Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon

作者: Christopher G. Azzoli

DOI: 10.1245/S10434-015-4704-Z

关键词:

摘要: Over a decade since the discovery of EGFR mutation, and 6 years prospective clinical trial data proved that routine molecular pathology tests improve survival in stage IV lung cancer, there is still debate whether to test patients with earlier stages disease (stage I–III). As discoveries targeted drugs for accelerate—prompting testing ALK, ROS1, RET, BRAF V600E, HER2, among others—there an argument all cancers should be genotyped purpose classification, regardless disease. The counterargument because have only been validated use disease, these need conducted at time recurrence. This review will describe current, practical applications early focusing on immediate diagnostic, prognostic, therapeutic implications individual patient management. Meanwhile, large-scale trials are underway as adjuvant therapies

参考文章(40)
Nael Martini, Myron R. Melamed, Multiple primary lung cancers. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 70, pp. 606- 612 ,(1975) , 10.1016/S0022-5223(19)40289-4
Benjamin Izar, Lecia Sequist, Mihan Lee, Alona Muzikansky, Rebecca Heist, John Iafrate, Dora Dias-Santagata, Douglas Mathisen, Michael Lanuti, The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers The Annals of Thoracic Surgery. ,vol. 96, pp. 962- 968 ,(2013) , 10.1016/J.ATHORACSUR.2013.05.091
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Odd R. Monge, Petri Bono, Raija Kallio, Aki Vehtari, Mika Leinonen, Thor Alvegård, Peter Reichardt, One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor JAMA. ,vol. 307, pp. 1265- 1272 ,(2012) , 10.1001/JAMA.2012.347
Sandra P. D’Angelo, Yelena Y. Janjigian, Nicholas Ahye, Gregory J. Riely, Jamie E. Chaft, Camelia S. Sima, Ronglai Shen, Junting Zheng, Joseph Dycoco, Mark G. Kris, Maureen F. Zakowski, Marc Ladanyi, Valerie Rusch, Christopher G. Azzoli, Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib Journal of Thoracic Oncology. ,vol. 7, pp. 1815- 1822 ,(2012) , 10.1097/JTO.0B013E31826BB7B2
Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire, Erik Thunnissen, Marc Ladanyi, Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Journal of Thoracic Oncology. ,vol. 8, pp. 823- 859 ,(2013) , 10.1097/JTO.0B013E318290868F
D. Ross Camidge, William Pao, Lecia V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer Nature Reviews Clinical Oncology. ,vol. 11, pp. 473- 481 ,(2014) , 10.1038/NRCLINONC.2014.104
Alice T. Shaw, Sai-Hong I. Ou, Yung-Jue Bang, D. Ross Camidge, Benjamin J. Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella-Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long Phi Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, Lesley M. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate, Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 371, pp. 1963- 1971 ,(2014) , 10.1056/NEJMOA1406766
David S Ettinger, Douglas E Wood, Wallace Akerley, Lyudmila A Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T Cheney, Lucian R Chirieac, Thomas A D’Amico, Todd L Demmy, Thomas J Dilling, M Chris Dobelbower, Ramaswamy Govindan, Frederic W Grannis, Leora Horn, Thierry M Jahan, Ritsuko Komaki, Lee M Krug, Rudy P Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W Loo, Renato Martins, Gregory A Otterson, Jyoti D Patel, Katherine M Pisters, Karen Reckamp, Gregory J Riely, Eric Rohren, Steven E Schild, Theresa A Shapiro, Scott J Swanson, Kurt Tauer, Stephen C Yang, Kristina Gregory, Miranda Hughes, None, Non–Small Cell Lung Cancer, Version 6.2015 Journal of The National Comprehensive Cancer Network. ,vol. 13, pp. 515- 524 ,(2015) , 10.6004/JNCCN.2015.0071
N.K. Altorki, M.E.R. O'brien, W.E.E. Eberhardt, F.C. Richardson, J. Wang, M.A. Foley, J.D. Horan, F.A. Shepherd, K. Kelly, Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results International Journal of Radiation Oncology Biology Physics. ,vol. 90, ,(2014) , 10.1016/J.IJROBP.2014.08.025
Nicolas Girard, Charuhas Deshpande, Christopher G. Azzoli, Valerie W. Rusch, William D. Travis, Marc Ladanyi, William Pao, Use of Epidermal Growth Factor Receptor/Kirsten Rat Sarcoma 2 Viral Oncogene Homolog Mutation Testing to Define Clonal Relationships Among Multiple Lung Adenocarcinomas : Comparison With Clinical Guidelines Chest. ,vol. 137, pp. 46- 52 ,(2010) , 10.1378/CHEST.09-0325